Amfamox;Antodine;Apo-Famotidine;Apogastine;Bestidine;Blocacid;Brolin;Cepal;Confobos;Cronol;Cuantin;Dibrit 40;Digervin;Dinul;Dipsin;Dispromil;Dispronil;Duovel;Durater;Evatin;Fadin;Fadine;Fadyn;Fagastine;Famo;Famocid;Famodar;Famodil;Famodin;Famodine;Famogard;Famonit;Famopsin;Famos;Famosan;Famotal;Famotep;Famotin;Famovane;Famowal;Famox;Famoxal;Famtac;Famulcer;Fanobel;Fanosin;Fanox;Farmotex;Ferotine;Fibonel;Fluxid;Fudone;Ganor;Gaster;Gastridan;Gastridin;Gastrion;Gastro;Gastrodomina;Gastrofam;Gastropen;Gastrosidin;H2 Bloc;Hacip;Huberdina;Ingastri;Invigan;Lecedil;Logos;Mensoma;Midefam;Mosul;Motiax;Muclox;Mylanta AR;Neocidine;Nevofam;Notidin;Novo-Famotidine;Nu-Famotidine;Nulceran;Nulcerin;Panalba;Pepcid;Pepcid AC;Pepcid RPD;Pepcidin;Pepcidin Rapitab;Pepcidina;Pepcidine;Pepdif;Pepdine;Pepdul;Pepfamin;Peptan;Peptidin;Peptifam;Pepzan;Purifam;Quamatel;Quamtel;Renapepsa;Restadin;Rogasti;Rubacina;Sedanium-R;Sigafam;Supertidine;Tairal;Tamin;Tipodex;Topcid;Ulcatif;Ulceprax;Ulcofam;Ulfagel;Ulfam;Ulfamid;Ulfinol;Ulgarine;Vagostal;Weimok;Whitidin;Yamarin;

Famotidina [Spanish];Famotidinum [Latin];

A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion. [PubChem]

• Abbott laboratories
• Actavis elizabeth llc
• Akorn strides llc
• Alembic ltd
• Apotex inc
• Apotex inc richmond hill
• Apothecon inc div bristol myers squibb
• App pharmaceuticals llc
• Baxter healthcare corp
• Baxter healthcare corp anesthesia and critical care
• Baxter healthcare internati0nal specialty therapies div
• Bedford laboratories div ben venue laboratories inc
• Ben venue laboratories inc
• Carlsbad technology inc
• Claris lifesciences ltd
• Dr reddys laboratories ltd
• Genpharm inc
• Hospira inc
• Ivax pharmaceuticals inc sub teva pharmaceuticals usa
• L perrigo co
• Lupin ltd
• Merck research laboratories div merck co inc
• Mutual pharmaceutical co inc
• Mylan pharmaceuticals inc
• Navinta llc
• Perrigo co
• Ranbaxy laboratories inc
• Salix pharmaceuticals inc
• Sandoz inc
• Schwarz pharma inc
• Teva pharmaceuticals usa inc
• Watson laboratories inc
• Wockhardt americas inc
• Wockhardt ltd

Synthesis Reference	Not Available
General Reference	Not Available

Form	Route	Strength
Solution	Intravenous
Tablet	Oral

Unit description	Cost	Unit
Pepcid 30 40 mg tablet Bottle	125.5 USD	bottle
Pepcid 40 mg/5ml Suspension 50ml Bottle	123.88 USD	bottle
Pepcid 30 20 mg tablet Bottle	64.13 USD	bottle
Mylanta Double-Strength 400-400-40 mg/5ml Suspension 710ml Bottle	10.15 USD	bottle
Mylanta 200-200-20 mg/5ml Suspension 710ml Bottle	9.23 USD	bottle
Mylanta 200-200-20 mg/5ml Suspension 355ml Bottle	7.99 USD	bottle
Mylanta Double-Strength 400-400-40 mg/5ml Suspension 355ml Bottle	7.99 USD	bottle
Famotidine 40 mg tablet	3.43 USD	tablet
Pepcid 40 mg tablet	3.02 USD	tablet
Famotidine powder	2.74 USD	g
Famotidine 20 mg tablet	1.76 USD	tablet
Pepcid 20 mg tablet	1.6 USD	tablet
Apo-Famotidine 40 mg Tablet	1.11 USD	tablet
Mylan-Famotidine 40 mg Tablet	1.11 USD	tablet
Novo-Famotidine 40 mg Tablet	1.11 USD	tablet
Nu-Famotidine 40 mg Tablet	1.11 USD	tablet
Pepcid ac 10 mg tablet	0.72 USD	tablet
Famotidine 40 mg/4 ml vial	0.71 USD	ml
Famotidine 500 mg/50 ml vial	0.71 USD	ml
Apo-Famotidine 20 mg Tablet	0.62 USD	tablet
Mylan-Famotidine 20 mg Tablet	0.62 USD	tablet
Novo-Famotidine 20 mg Tablet	0.62 USD	tablet
Nu-Famotidine 20 mg Tablet	0.62 USD	tablet
Pepcid ac 20 mg tablet	0.58 USD	tablet
Famotidine-ns 20 mg/10 ml syrg	0.54 USD	ml
Pepcid ac 10 mg gelcap	0.48 USD	capsule
Pepcid complete tablet chew	0.4 USD	tablet
Famotidine 20 mg/2 ml vial	0.36 USD	ml
Famotidine 10 mg/ml vial	0.28 USD	ml
CVS Pharmacy acid controller 20 mg tablet	0.24 USD	tablet
CVS Pharmacy acid controller tablet	0.24 USD	tablet
Acid reducer 20 mg tablet	0.22 USD	tablet
Acid controller 10 mg tablet	0.21 USD	tablet
Mylanta gas 125 mg tablet chew	0.16 USD	tablet
Acid reducer 10 mg tablet	0.15 USD	tablet
Famotidine 10 mg tablet	0.15 USD	tablet
Famotidine 20 mg piggyback	0.13 USD	ml
Mylanta gelcap	0.12 USD	capsule
Mylanta ultimate-strength tablet	0.07 USD	tablet
Mylanta ultra chew tablet	0.06 USD	tablet
Pv acid reducer 10 mg tablet	0.05 USD	tablet
Mylanta liq	0.02 USD	ml
Mylanta supreme antacid liq	0.02 USD	ml

Type	small molecule

Classes

Sulfonyls Sulfuric Acids and Derivatives Thiazoles

Substructures

Ethers Sulfonyls Sulfuric Acids and Derivatives Thiazoles Heterocyclic compounds Guanidines Aromatic compounds Carboxamidines Imines

gastric acid RELATED DISORDERS 中和胃酸;

Indication	For the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD).
Pharmacodynamics	Famotidine, a competitive histamine H2-receptor antagonist, is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Famotidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Famotidine include an increase in gastric bacterial flora such as nitrate-reducing organisms.
Mechanism of action	Famotidine binds competitively to H2-receptors located on the basolateral membrane of the parietal cell, blocking histamine affects. This competitive inhibition results in reduced basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin.
Absorption	The bioavailability of oral doses is 40-45%.
Volume of distribution	Not Available
Protein binding	15-20%
Metabolism	Hepatic.
Route of elimination	Renal clearance is 250-450 mL/min, indicating some tubular excretion.
Half life	2.5-3.5 hours
Clearance	renal cl=250-450 mL/min
Toxicity	Intravenous, mouse: LD50 = 244.4mg/kg; Oral, mouse: LD50 = 4686 mg/kg. Symptoms of overdose include emesis, restlessness, pallor of mucous membranes or redness of mouth and ears, hypotension, tachycardia and collapse.
Affected organisms	Humans and other mammals
Pathways	Pathway Name SMPDB ID Famotidine Pathway SMP00231

Properties
State	solid
Melting point	163-164 oC
Experimental Properties	Property Value Source water solubility 1.1 mg/mL PhysProp logP -2.1 PhysProp
Predicted Properties	Property Value Source water solubility 2.71e-01 g/l ALOGPS logP -0.20 ALOGPS logP -2.16 ChemAxon Molconvert logS -3.10 ALOGPS pKa ChemAxon Molconvert hydrogen acceptor count 8 ChemAxon Molconvert hydrogen donor count 4 ChemAxon Molconvert polar surface area 175.83 ChemAxon Molconvert rotatable bond count 6 ChemAxon Molconvert refractivity 80.46 ChemAxon Molconvert polarizability 32.02 ChemAxon Molconvert

Drug	Interaction
Atazanavir	This gastric pH modifier decreases the levels/effects of atazanavir
Enoxacin	Famotidine may decrease the absorption of enoxacin.
Itraconazole	The H2-receptor antagonist, famotidine, may decrease the absorption of itraconazole.
Ketoconazole	The H2-receptor antagonist, famotidine, may decrease the absorption of ketoconazole.

• Avoid alcohol.
• Limit caffeine intake.
• Take without regard to meals, food may slightly increase the product's bioavailability.